Antiviral therapy

Abstract

The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC

What is claimed is: 
     
         1 . A method of treating HIV infection by administering to a subject the compound of formula (I) 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, with a therapeutic agent that is the active ingredient tenofavir in the subject. 
     
     
         2 . The method of  claim 1  wherein the therapeutic agent is a fumaric acid salt. 
     
     
         3 . The method of  claim 2  further comprising administering a nucleoside reverse transcriptase inhibitor. 
     
     
         4 . The method of  claim 1 , wherein the subject is administered a composition comprising 20-300 mg of the compound of formula (I) or an equivalent dose of a pharmaceutically acceptable salt thereof, 20-300 mg of a fumaric acid salt of a therapeutic agent that is the active ingredient tenofavir in the subject, and 20-300 mg of a nucleoside reverse transcriptase inhibitor. 
     
     
         5 . A method according to  claim 4  wherein the composition is given once a day. 
     
     
         6 . A method according to  claim 4  wherein the composition is in unit dosage form. 
     
     
         7 . A pharmaceutical composition comprising a compound of formula (I) 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, with a therapeutic agent that is the active ingredient tenofavir in the subject. 
     
     
         8 . The pharmaceutical composition according to  claim 7  wherein the the therapeutic agent is a fumaric acid salt. 
     
     
         9 . The pharmaceutical composition according to  claim 7  further comprising a nucleoside reverse transcriptase inhibitor. 
     
     
         10 . The pharmaceutical composition according to  claim 7  in a unit dosage form. 
     
     
         11 . The pharmaceutical composition according to  claim 7  comprising 20-300 mg of the compound of formula (I) or an equivalent dose of a pharmaceutically acceptable salt thereof, 20-300 mg of a fumaric acid salt of a therapeutic agent that is the active ingredient tenofavir in the subject, and 20-300 mg of a nucleoside reverse transcriptase inhibitor. 
     
     
         12 . The pharmaceutical composition according to  claim 11  in unit dosage form. 
     
     
         13 . A combination comprising as active ingredients, the compound of formula (I), 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, tenofovir, and a nucleoside reverse transcriptase inhibitor. 
     
     
         14 . The combination of  claim 13  in unit dosage form. 
     
     
         15 . A combination comprising as active ingredients 20-300 mg of the compound of formula (I), 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, 20-300 of tenofovir, and 20-300 mg of a nucleoside reverse transcriptase inhibitor. 
     
     
         16 . The combination of  claim 15  in unit dosage form.